TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03176446

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with traditional technique
Description: Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with computerized technique
Description: Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with DentalVibe technique
Description: Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topic anesthesia
Description: Application of topical anesthetic for 60 seconds with benzocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topic anesthesia
Description: Application of topical anesthetic for 60 seconds with benzocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topic anesthesia
Description: Application of topical anesthetic for 60 seconds with benzocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic
Description: 2% lidocaine with epinephrine 1: 100000 1.8 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic
Description: 2% lidocaine with epinephrine 1: 100000 1.8 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic
Description: 2% lidocaine with epinephrine 1: 100000 1.8 mL
Study: NCT02108145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral metal stent insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral metal stent insertion
Study: NCT00781534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginseng
Description: Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginseng

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ginsenoside RE
Description: active metabolite of ginseng

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: placebo group
Study: NCT02050919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT00076752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Conditioning and transplant regimen: 30 mg/m\^2 day intravenous infusion over 30 minutes daily, 4 days (transplant days -6, -5, -4, -3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Priming regimen: 2000 mg/m\^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m\^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituxan (rituximab)
Description: Priming regimen: 375 mg/m\^2 intravenous day 1, 4. Conditioning and transplant regimen: 750 mg/m\^2 intravenous infusion, day -7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Priming regimen: 10 micrograms/kg/day subcutaneous, starting day 6. Conditioning and transplant regimen: 5 micrograms/kg/day subcutaneous, day +1 until ANC \>500 microliters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Priming regimen:1000 mg intravenous over 30 minutes, day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Lymphoablative regimen using cyclophosphamide, rituximab, and fludarabine followed by a CD34 cell selected autologous stem cell transplant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Standard human immunology research laboratory ex vivo studies.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Conditioning and transplant regimen 25-50 mg orally or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Priming regimen: 600 mg/m\^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m\^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.
Study: NCT01864915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
Study: NCT02829333

Intervention type: OTHER
Group type: OTHER
Intervention: general anesthesia and patient controlled intravenous analgesia
Description: Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation

Intervention type: OTHER
Group type: OTHER
Intervention: spinal anesthesia and continuous postoperative epidural analgesia
Description: Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation
Study: NCT03791203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction (MACR)
Description: This was a randomized, single-blind controlled trial with modified alternate-day calorie restriction (MACR) as the active intervention and normal habitual diet as control at Hospital University of Sains Malaysia.
Study: NCT01874106

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Therapy
Description: The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
Study: NCT03811106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuromuscularElectricalStimulation+ConventionalPhysiotherapy
Description: Sırt ekstansör kaslarına nöromusküler elektrik stimülasyonu uygulanacaktır

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physiotherapy and rehabilitation
Description: Konvansiyonel fizyoterapi ve rehabilitasyon uygulamaları yapılacaktır.
Study: NCT01683240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cholangioscopy (Frimberger)
Description: cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
Study: NCT02273297

Intervention type: OTHER
Intervention: Maternal factors
Study: NCT01710917

Intervention type: DRUG
Intervention: Targinact® (oxycodon/naloxon)
Study: NCT01589952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegalyted interferon, Entecavir
Description: Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks Entecavir: 0.5 mg orally once daily for 24 weeks
Study: NCT00692406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Abstinence
Description: Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
Study: NCT02702700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, liposomal
Description: Lipoplatin IV 200 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin
Description: Visudyne® IV 3 mg/m2

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry
Description: Intrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of \<10mWcm2.
Study: NCT00543660

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)
Study: NCT01762423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Device (IVIVI SofPulse)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Study: NCT03324711

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Antillanisée Mini Mental State Examination (MMSEa)
Description: Antillanisée version of the Mini Mental State Examination (MMSEa), is a version adaptated to the French West Indies creole culture.
Study: NCT02534532

Intervention type: OTHER
Intervention: AF screening
Description: Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
Study: NCT04060225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: Starbuck's brand blonde roast coffee, 20 ounces
Study: NCT04654247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality audit and feedback
Description: Endoscopists received quality report generated by Endo.Adm.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: None feedback.
Study: NCT01377558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic endurance training intervention
Description: The aerobic endurance training group will use cardiovascular training devices~week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week~week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week~week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength endurance training intervention
Description: The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)~week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week~week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined aerobic endurance and strength endurance training
Description: week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week~week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week
Study: NCT02235701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 170 mg/m2 aldoxorubicin
Description: administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
Study: NCT01864915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon Capsule
Description: Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon Capsule
Description: Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon Capsule
Description: Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.
Study: NCT03546426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV q3w until disease progression, unacceptable toxicity or informed consent withdrawal, or for a maximum of 2 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells
Description: Autologous dendritic cells (DC) loaded with autologous tumor homogenate, 10 x7 cells ID every 3 weeks for up to six doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 3 MU s.c. from day +2 to day +6 after each DC administration
Study: NCT00749684

Intervention type: BIOLOGICAL
Intervention: Interferon α-2b
Description: 20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.
Study: NCT02796352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose bolus interleukin-2 (HD IL2)
Description: Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).~The planned treatment consists of 3 courses (6 cycles) of HD IL-2.
Study: NCT03665922

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BroccoMax®
Description: Nutraceutical neoadjuvant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control
Study: NCT04885179

Intervention type: OTHER
Intervention: no intervention
Description: No interventions are involved in this observational study.

Intervention type: OTHER
Intervention: no intervention
Description: No interventions are involved in this observational study.

Intervention type: OTHER
Intervention: no intervention
Description: No interventions are involved in this observational study.
Study: NCT04181983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized exercise program
Description: Home-based personalized exercise program using a smart phone app

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WHO exercise guidelines
Description: Standard exercise counselling according to WHO guidelines
Study: NCT02235701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg/m2 aldoxorubicin
Description: administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
Study: NCT01155037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine against H1N1 influenza virus (GSK)
Description: Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted vaccine against H1N1 influenza virus (GSK)
Description: Patients infected with HIV will receive 7.5 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted vaccine against H1N1 influenza virus (GSK)
Description: Control group will receive 3.75 µg of an adjuvanted A H1N1 vaccine in one single application.
Study: NCT01086566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Description: Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Description: Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Description: Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Description: Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005
Description: Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
Study: NCT04746651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Self Help
Description: Guided self help appointments with prison staff - 4x 30 minute appointments.
Study: NCT01920503

Intervention type: DRUG
Intervention: Doxorubicin
Description: Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
Study: NCT02224482

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROGRESS
Description: PROGRESS is a multimedia website designed to help prostate cancer survivors.
Study: NCT03322774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment.
Study: NCT01729234

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate
Description: Dietary Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary Supplement
Study: NCT04636606

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise
Description: Educational training program about oral dysphagia in patients with temporomandibular disorders.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy Combined with Home Exercise
Description: Manual therapy program combined with educational training program about oral dysphagia in patients with temporomandibular disorders.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial Myofunctional Therapy combined with Manual Therapy and Home Exercise
Description: Orofacial Myofunctional Therapy program with combination of Manual therapy and educational training program about oral dysphagia in patients with temporomandibular disorders.
Study: NCT02225977

Intervention type: DRUG
Intervention: Gilenya

Intervention type: DRUG
Intervention: Gilenya

Intervention type: DRUG
Intervention: Gilenya

Intervention type: DRUG
Intervention: Gilenya
Study: NCT01918319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
Study: NCT03863197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive strength training
Description: Progressive Supervised Home-based Strength Training
Study: NCT04156997

Intervention type: OTHER
Intervention: No intervention is involved in this study
Description: No intervention is involved in this study

Intervention type: OTHER
Intervention: No intervention is involved in this study
Description: No intervention is involved in this study
Study: NCT04034459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg BW iv over 30 to 90\* min day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 150 mg/m² iv, 30 - 90 min. day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150 mg/m² iv, 30 - 90 min. day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid
Description: Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m² day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85mg/m² day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU 3000 mg/m² iv over 48 h days 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 3000 mg/m² iv over 48 h days 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8
Study: NCT01988896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose as specified via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose as specified via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.